Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis

By sjmartinez • July 16, 2024

Paik JJ, Vencovský J, Charles-Schoeman C, Wright GC, Vleugels RA, Goriounova AS, Mudd PN Jr, Aggarwal R. Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis. Clin Exp Rheumatol. 2024 Jul 15. doi: 10.55563/clinexprheumatol/eeglsa. Epub ahead of print. PMID: 39008325.

Tags: Publications, Rheumatology

Communicating Precision Medicine Research: Multidisciplinary Teams and Diverse Communities

Beans JA, Trinidad SB, Blacksher E, Hiratsuka VY, Spicer P, Woodahl EL, Boyer BB, Lewis CM Jr, Gaffney PM, Garrison NA, Burke W. Communicating Precision[...]

A Spanish-language educational intervention to enhance diabetes outcomes among existing continuous glucose monitor users in a federally qualified health care center

Tavares M, Khoshbin K, Solorzano W, Scarlett L, Santana C, Lopez R, Villanueva GP, Escobar B, Mangual KS, Pavlish C, Bush NJ, Moin T, Everett[...]

Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity

Heskett MB, Vouzas AE, Johnstone B, Freese KP, Yates PA, Copenhaver PF, Spellman PT, Gilbert DM, Thayer MJ. Autosomal allelic inactivation at loci with variable[...]